Abbott Laboratories on Wednesday forecast 2025 profit that came in line with Wall Street estimates as it expects new device ...

Morgan Stanley analyst Patrick Wood maintained a Hold rating on Abbott Laboratories (ABT – Research Report) yesterday and set a price target of ...

The lawsuit accuses the formula maker of deceptively marketing the milks to make them seem like the next recommended step for toddlers.

The company’s projected adjusted diluted EPS for 2025 is between $5.05 and $5.25, marking double-digit growth at the midpoint. Abbott’s first-quarter 2025 adjusted EPS is expected to be between $1.05 ...

Abbott Laboratories on Wednesday forecast annual profit in line with Wall Street estimates, as it expects elevated ...

Analyst Lee Hambright of Bernstein maintained a Buy rating on Abbott Laboratories (ABT – Research Report), boosting the price target to ...

For 2025, Abbott forecast organic sales growth of between 7.5% and 8.5%, as well as adjusted earnings per share of $5.05 to $5.25. Analysts expect $5.16 a share on $42 billion in sales.

Formulas marketed for toddlers are a burgeoning business, but pediatricians have long recommended against their use.

A legal research organization focused on public health says Abbott Laboratories' marketing of "toddler milk" products to children age 12 months to 36 months as "natural and healthy" is misleading.

ABT gains a key position in point-of-care testing, focusing on Infectious Disease, Cardiometabolic & Informatics, Toxicology and Consumer Diagnostics.

Abbott has received an innovation award for Lingo, its first consumer biowearable over-the-counter device designed to support ...

Abbott has won an innovation award for Lingo, its first consumer biowearable over-the-counter device that helps people ...